Ranbaxy Laboratories, one of the leading pharma players, reported consolidated net profit of Rs 4.78 billion for the quarter ended Sept. 30, 2014 as compared to net loss of Rs 4.54 billion in the same period last year.

Total income came at Rs 32.60 billion, an increase of 16.35% over Rs 28.02 million in the same period a year ago.

EBITDA was Rs 8,071 million. Base business margins in line with the corresponding quarter last year.

Arun Sawhney, CEO & MD Ranbaxy, said, ''During the quarter, growth in base business was driven by India and Western Europe. In the US, we successfully launched Valsartan with 180 days exclusivity. Our focus continues to be on creating brands and providing differentiated products as future growth drivers.''

Shares of the company gained Rs 32.5, or 5.44%, to trade at Rs 630.10. The total volume of shares traded was 438,369 at the BSE (1.53 p.m., Tuesday).